NKTRNasdaqPharmaceutical PreparationsFiscal year ends December 31
NEKTAR THERAPEUTICS
Financials through Q4 FY2025, quarter ended Dec 31, 2025Last filing: 10-Q on Aug 14, 2026
$36.64+0.86 (+2.40%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
NEKTAR THERAPEUTICS revenue by segment
By business segment
By product or service
| Revenue | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | TTM Q2 23 | TTM Q1 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-cash royalty revenue related to the sales of future royalties | $54.93M | $49.36M | $53.60M | $59.22M | $64.27M | $66.09M | $68.53M | $67.57M | $68.92M | $68.49M | $68.66M | $69.13M | 99.5% | -14.5% |
| License, collaboration and other revenue | $300.00K | $363.00K | $441.00K | $500.00K | $597.00K | $875.00K | $652.00K | $602.00K | $520.00K | $196.00K | $355.00K | $355.00K | 0.5% | -49.7% |
| Product sales | $0 | $12.87M | $20.89M | $27.53M | $33.56M | $26.17M | $23.98M | $22.00M | $20.68M | $19.58M | $18.72M | $19.38M | 0.0% | -100.0% |
By region
From the segment and revenue-disaggregation notes of Nektar Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.